Assessing the state of Medicaid coverage for gene and cell therapies
Mol Ther
.
2022 Sep 7;30(9):2879-2880.
doi: 10.1016/j.ymthe.2022.08.009.
Epub 2022 Aug 26.
Authors
Diane Berry
1
,
Jennifer Wellman
2
,
Jeremy Allen
3
,
Christina Mayer
4
Affiliations
1
Sarepta Therapeutics, Inc., Cambridge, MA, USA.
2
Akouos, Inc., Boston, MA, USA.
3
Spark Therapeutics, Inc., Philidelphia, PA, USA.
4
American Society of Gene & Cell Therapy, Waukesha, WI, USA. Electronic address: cmayer@asgct.org.
PMID:
36029768
PMCID:
PMC9482011
DOI:
10.1016/j.ymthe.2022.08.009
No abstract available
MeSH terms
Health Services Accessibility*
Medicaid*
United States